Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements.

This concurrent resolution expresses the sense of Congress that (1) the efficient administration of Medicare and Medicaid encompasses federal efforts to achieve good value for funds spent in those programs; (2) the Centers for Medicare & Medicaid Services (CMS) has the authority to require direct-to-consumer television advertisements of prescription drugs and biological products to include the drug or product's list price; (3) the final rule by the CMS published in the Federal Register on May 10, 2019, makes substantial progress in improving drug pricing transparency; and (4) such rule should be enacted into law.